Literature DB >> 20717655

Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women.

Rajaa A Mirghani1, Ishraga Elagib, Gehad Elghazali, Urban Hellgren, Lars L Gustafsson.   

Abstract

PURPOSE: The study aimed to investigate the effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women.
METHODS: In a case-control study, nine pregnant and eight non-pregnant Sudanese women infected with P. falciparum were treated with intramuscular artemether. Before being given artemether, they received a single dose of quinine hydrochloride as intravenous infusion. Blood samples were collected frequently and analysed for quinine and its metabolites (phase I). One week later (after clearance of parasitaemia) the quinine part of the protocol was repeated (phase II).
RESULTS: During phase I, the AUCs (mean ± SD) of quinine and its major metaboplite, 3-hydroxyquinine, in pregnant women were 428.2 ± 132.4 and 27.8 ± 14.1 μmol l(-1) h(-1) respectively. In non-pregnant women the AUCs of quinine and 3-hydroxyquinine were 517.8 ± 100.0 and 32.3 ± 15.3 μmol l(-1) h(-1). In pregnant women the mean (90% confidence interval) AUC ratios of phase I to phase II of quinine and 3-hydroxyquinine were 1.6 (0.61, 4.22) and 1.01 (0.18, 5.60). In non-pregnant women, the AUC ratios of phase I to phase II of quinine and 3-hydroxyquinine were 1.93 (1.74, 2.15) and 1.19 (0.95, 1.47).
CONCLUSIONS: Plasmodium falciparum infection significantly increased plasma concentration of quinine in non-pregnant women and showed the same trend in pregnant women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717655     DOI: 10.1007/s00228-010-0877-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  32 in total

Review 1.  Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  2000-04       Impact factor: 2.184

2.  Maternal sex hormones in early pregnancy and asthma among offspring: a case-control study.

Authors:  Baizhuang Xu; Juha Pekkanen; Tuula Husman; Leea Keski-Nisula; Pentti Koskela
Journal:  J Allergy Clin Immunol       Date:  2003-12       Impact factor: 10.793

3.  Midazolam and cortisol metabolism before and after CYP3A induction in humans.

Authors:  S L Eeckhoudt; J P Desager; A R Robert; I Leclercq; R K Verbeeck; Y Horsmans
Journal:  Int J Clin Pharmacol Ther       Date:  2001-07       Impact factor: 1.366

4.  Quinine and severe falciparum malaria in late pregnancy.

Authors:  S Looareesuwan; N J White; K Silamut; R E Phillips; D A Warrell
Journal:  Acta Leiden       Date:  1987

5.  Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography.

Authors:  R A Mirghani; O Ericsson; J Cook; P Yu; L L Gustafsson
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-15

6.  No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.

Authors:  K Laine; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

7.  Quinine and severe falciparum malaria in late pregnancy.

Authors:  S Looareesuwan; R E Phillips; N J White; S Kietinun; J Karbwang; C Rackow; R C Turner; D A Warrell
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

Review 8.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

9.  Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.

Authors:  Sanna Palovaara; Olavi Pelkonen; Jouko Uusitalo; Stefan Lundgren; Kari Laine
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

10.  Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.

Authors:  S J Kovacs; D E Martin; D E Everitt; S D Patterson; D K Jorkasky
Journal:  Clin Pharmacol Ther       Date:  1998-06       Impact factor: 6.875

View more
  4 in total

Review 1.  Pharmacokinetics of antimalarials in pregnancy: a systematic review.

Authors:  Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

2.  Plasmodium falciparum resistance to cytocidal versus cytostatic effects of chloroquine.

Authors:  Michelle F Paguio; Kelly L Bogle; Paul D Roepe
Journal:  Mol Biochem Parasitol       Date:  2011-04-04       Impact factor: 1.759

3.  Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review.

Authors:  Teerachat Saeheng; Kesara Na-Bangchang
Journal:  Malar J       Date:  2022-02-10       Impact factor: 2.979

4.  Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda.

Authors:  Joel Tarning; Frank Kloprogge; Mehul Dhorda; Vincent Jullien; Francois Nosten; Nicholas J White; Philippe J Guerin; Patrice Piola
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.